PharmaTelevision - Rexahn Pharmaceuticals: Saving Lives Through Innovation

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Rexahn Pharmaceuticals: Saving Lives Through Innovation

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Rick Soni, Chief Operating Officer at Rexahn Pharmaceuticals, an innovative biopharmaceutical company.

They discuss:

• Rexahn’s areas of focus: CNS and Oncology
• the company’s 3 Phase II products
• partnering with Big Pharma and Rexahn’s current partnership with Teva
• Rexahn’s plans for the future

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Rexahn's areas of focus: CNS and Oncology.

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in San Francisco at BioPharm America. On this show I have Rick Soni, who is President and Chief Operating Officer of the company called Rexahn Pharmaceuticals based in Maryland here in the United States. Welcome to the show.

Rick Soni:

Thank you Fintan Walton.

Fintan Walton:

Rick Soni,Rexahn Pharmaceuticals company is a specialty type pharmaceutical company, could you describe what that company actually focuses on?

Rick Soni:

Yes Fintan Walton, Rexahn Pharmaceuticals was founded in 2001 by Dr. Chang Ahn. And his mission was to save patient lives and improve quality of life. Our focus is in two therapeutic areas CNS and oncology. We are listed on Amex.

Fintan Walton:

Right.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Rick Soni

President and COO

Rick Soni joined Rexahn Pharmaceuticals in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn Pharmaceuticals, Rick held several leadership roles at Otsuka America Pharmaceuticals, Inc, with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Rick has held a variety of management positions at Novartis and Schering-Plough. Rick Soni has a BS from University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Rexahn Pharmaceuticals

Rexahn Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system -CNS- disorders and other unmet medical needs. Its motto, "Saving Lives Through Innovation," represents the Company's use of scientific innovation to improve the health and wellness of patients. Rexahn Pharmaceuticals develops therapies that treat specific disease states, while minimizing side effects in order to help patients regain quality of life during treatment. Rexahn Pharmaceuticals currently has three clinical stage drug candidates: ArchexinTM, SerdaxinTM andZoraxelTM. Further, Rexahn Pharmaceuticalsleverages proprietary nanomedicine research and multi-target aimed ligands platform to strengthen its preclinical pipeline, and develop cancer drugs that offer greater therapeutic benefits and quality of life for patients. Rexahn Pharmaceuticals is based in Rockville, Maryland and is currently traded on the NYSE Amex under the symbol RNN.